Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Telomir Pharmaceuticals / Equity Bottom-Up

<ul>
<li>Telomir Pharmaceuticals is a preclinical stage company focused on the science of lengthening telomere caps, which the company believes will extend human lifespans and improve quality of life as people age.</li>
<li>Preclinical tests showed that the company's signature therapy, Telomir-1, appeared to address insulin resistance and achieving reversal to near pre-diabetic levels.</li>
<li>These results add to previous testing results showing a myriad of potential life improving and extending benefits.</li>
</ul>


Telomir Pharmaceuticals is a preclinical stage company focused on the science of lengthening telomere caps, which the company believes will extend human lifespans and improve quality of life as people age.
Preclinical tests showed that the company's signature therapy, Telomir-1, appeared to address insulin resistance and achieving reversal to near pre-diabetic levels.
These results add to previous testing results showing a myriad of potential life improving and extending benefits.


United States

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company focuses on the development and commercialization of telomir 1, a novel treatment that drive the concentration and accumulation of iron and copper in the serum that affects diseases like hemochromatosis and cancer. Telomir Pharmaceuticals serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Telomir Pharmaceuticals (TELO US)

TELO: Another Potential Breakthrough

Preclinical tests showed that the company's signature therapy, Telomir-1, appeared to address insulin resistance and achieving reversal to near pre...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)